Immunotech Biopharm’s CAR-T-19 Gains Breakthrough Status

Immunotech Biopharm Ltd (HK:6978) has released an update.

Immunotech Biopharm Ltd has announced that its CAR-T-19 Injection, designed for young patients with relapsed or refractory B-cell acute lymphoblastic leukemia, has received breakthrough therapy designation from China’s National Medical Products Administration. This designation is expected to fast-track the drug’s clinical development, providing early access to patients. The company’s focus on innovative cellular immunotherapy continues to drive its progress in the biopharmaceutical landscape.

For further insights into HK:6978 stock, check out TipRanks’ Stock Analysis page.